Access significant technical and cross-functional experience for your COVID-19 testing needs. As the world’s leading network of clinical research central labs, Labcorp Drug Development Central Laboratories delivers globally consistent, actionable data to drive your COVID-19 studies forward – faster.
Extract the most value out of our globally integrated central laboratory network with the help of our scientific and operational experts. With deep experience gained from more than 4,400 clinical trials during the past five years across all therapeutic areas, we know how to optimize your studies and mitigate potential issues to meet the fast-pace associated with coronavirus (COVID-19) studies.
Several assays for COVID-19 are undergoing expedited validation to meet trial testing standards.
Assay panels that can be used to exclude other respiratory illnesses are already validated to meet clinical trial testing standards.
Each year, we generate over 55 million reported results. (source: Labcorp Drug Development CLA Internal Metrics 2018)
To speed up study startups, we've created a the Streamlined Study Start-Up (SSSU) team to help liaise with key departments to shorten timelines. We've seen unprecented speeds, including a 5-business-day turnaround.
Discover how technology innovation expedites your study startup.
Proprietary method approved for use in COVID-19 trials:
Hydroxychloroquine
Related Laboratory Content
GeneXpert® is a trademark of Cepheid
BioFire® FilmArray® is a trademark of BioFire Diagnostics LLC
Connect with our COVID-19 Response Team
Contact Us
Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.
.png){kind=icon}